A detailed history of Principal Financial Group Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 2,005,905 shares of IOVA stock, worth $16.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,005,905
Previous 2,636,327 23.91%
Holding current value
$16.1 Million
Previous $21.4 Million 38.7%
% of portfolio
0.02%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

SELL
$7.59 - $17.47 $4.78 Million - $11 Million
-630,422 Reduced 23.91%
2,005,905 $29.7 Million
Q4 2023

Feb 07, 2024

SELL
$3.3 - $8.89 $22,532 - $60,700
-6,828 Reduced 0.26%
2,636,327 $21.4 Million
Q3 2023

Nov 02, 2023

BUY
$4.44 - $8.79 $3.43 Million - $6.79 Million
772,905 Added 41.33%
2,643,155 $12 Million
Q2 2023

Aug 07, 2023

SELL
$5.36 - $9.06 $227,917 - $385,249
-42,522 Reduced 2.22%
1,870,250 $13.2 Million
Q1 2023

May 09, 2023

BUY
$5.53 - $8.22 $4.87 Million - $7.24 Million
881,181 Added 85.42%
1,912,772 $11.7 Million
Q4 2022

Feb 09, 2023

SELL
$5.62 - $10.0 $201,426 - $358,410
-35,841 Reduced 3.36%
1,031,591 $6.59 Million
Q3 2022

Nov 09, 2022

BUY
$9.53 - $13.11 $1.44 Million - $1.98 Million
150,749 Added 16.45%
1,067,432 $10.2 Million
Q2 2022

Aug 10, 2022

BUY
$6.38 - $18.33 $2.23 Million - $6.42 Million
350,025 Added 61.77%
916,683 $10.1 Million
Q1 2022

May 09, 2022

BUY
$12.38 - $19.1 $62,778 - $96,856
5,071 Added 0.9%
566,658 $9.44 Million
Q4 2021

Feb 09, 2022

BUY
$16.55 - $27.63 $243,616 - $406,713
14,720 Added 2.69%
561,587 $10.7 Million
Q3 2021

Nov 09, 2021

BUY
$20.35 - $26.63 $443,304 - $580,107
21,784 Added 4.15%
546,867 $13.5 Million
Q2 2021

Aug 10, 2021

BUY
$16.33 - $33.07 $1.73 Million - $3.51 Million
106,211 Added 25.36%
525,083 $13.7 Million
Q1 2021

May 10, 2021

BUY
$28.67 - $52.59 $1.07 Million - $1.97 Million
37,419 Added 9.81%
418,872 $13.3 Million
Q4 2020

Feb 08, 2021

BUY
$28.04 - $50.26 $302,243 - $541,752
10,779 Added 2.91%
381,453 $17.7 Million
Q3 2020

Nov 06, 2020

BUY
$27.75 - $36.3 $22,366 - $29,257
806 Added 0.22%
370,674 $12.2 Million
Q2 2020

Aug 05, 2020

BUY
$27.21 - $41.0 $4.86 Million - $7.33 Million
178,760 Added 93.54%
369,868 $10.2 Million
Q1 2020

May 12, 2020

BUY
$19.54 - $38.85 $1.74 Million - $3.45 Million
88,858 Added 86.9%
191,108 $5.72 Million
Q4 2019

Feb 05, 2020

BUY
$17.95 - $29.41 $1.18 Million - $1.93 Million
65,635 Added 179.26%
102,250 $2.83 Million
Q3 2019

Nov 13, 2019

BUY
$17.99 - $26.0 $59,420 - $85,878
3,303 Added 9.92%
36,615 $666,000
Q2 2019

Aug 12, 2019

BUY
$9.78 - $24.52 $40,049 - $100,409
4,095 Added 14.02%
33,312 $817,000
Q1 2019

May 10, 2019

BUY
$8.41 - $11.26 $36,331 - $48,643
4,320 Added 17.35%
29,217 $278,000
Q4 2018

Feb 14, 2019

SELL
$7.51 - $11.93 $32,570 - $51,740
-4,337 Reduced 14.84%
24,897 $220,000
Q3 2018

Nov 14, 2018

BUY
$11.25 - $17.7 $46,215 - $72,711
4,108 Added 16.35%
29,234 $329,000
Q2 2018

Aug 13, 2018

BUY
$12.45 - $16.95 $312,818 - $425,885
25,126 New
25,126 $0

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.27B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.